Edgestream Partners L.P. Grows Position in Danaher Corporation $DHR

Edgestream Partners L.P. boosted its position in shares of Danaher Corporation (NYSE:DHR) by 698.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,960 shares of the conglomerate’s stock after purchasing an additional 21,832 shares during the period. Edgestream Partners L.P.’s holdings in Danaher were worth $4,931,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. IFG Advisory LLC grew its position in Danaher by 49.0% in the 1st quarter. IFG Advisory LLC now owns 2,217 shares of the conglomerate’s stock valued at $454,000 after acquiring an additional 729 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Danaher by 1.9% during the first quarter. Commonwealth Equity Services LLC now owns 144,868 shares of the conglomerate’s stock valued at $29,698,000 after purchasing an additional 2,753 shares during the period. Earned Wealth Advisors LLC bought a new position in shares of Danaher in the first quarter worth about $241,000. Probity Advisors Inc. increased its stake in Danaher by 5.2% in the 1st quarter. Probity Advisors Inc. now owns 1,312 shares of the conglomerate’s stock worth $269,000 after buying an additional 65 shares during the period. Finally, Advyzon Investment Management LLC lifted its holdings in Danaher by 65.6% during the 1st quarter. Advyzon Investment Management LLC now owns 1,586 shares of the conglomerate’s stock valued at $325,000 after buying an additional 628 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 3,298 shares of the company’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the transaction, the director directly owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. This represents a 13.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. The trade was a 59.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 30,248 shares of company stock worth $6,609,663 over the last three months. Corporate insiders own 11.20% of the company’s stock.

Danaher Trading Up 1.2%

Shares of NYSE DHR opened at $226.82 on Wednesday. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23. The business has a fifty day moving average price of $213.63 and a 200 day moving average price of $203.77. The stock has a market capitalization of $160.21 billion, a P/E ratio of 46.77, a price-to-earnings-growth ratio of 4.35 and a beta of 0.89. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10.

Danaher (NYSE:DHR) last posted its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. The company had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.71 earnings per share. Equities research analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were given a dividend of $0.32 per share. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s dividend payout ratio is presently 26.39%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Cowen reaffirmed a “buy” rating on shares of Danaher in a research report on Wednesday, October 22nd. Robert W. Baird set a $247.00 price objective on Danaher in a report on Wednesday, October 22nd. Rothschild Redb lowered Danaher from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 8th. Evercore ISI increased their price target on Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Finally, Bank of America cut their price target on Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Twenty investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $245.75.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.